In NSCLC with EGFR exon 20 insertion mutations showing intrinsic resistance to approved TKIs, for which the standard of care remains platinum-based chemotherapy with an associated reduced median overall OS of 16 months [90], amivantamab, by its capacity to bind to the extracellular part of each receptor domain, is able to bypass the resistance at the binding site of the TKI, demonstrating clinically meaningful efficacy in these patients [91]. Here, EGFR is linked to non-small cell lung carcinoma.